PAUL R. MCCURDY, M.D., F.A.C.P.; ROBERT F. DONOHOE, M.D.; MALCOLM MAGOVERN, M.D.
Pyrazinoic acid amide1 was introduced in 1952 for the treatment of tuberculosis. It was soon found to have significant hepatic toxicity and to produce an increase of serum uric acid which occasionally resulted in acute gouty arthritis. Since it offered no advantage over available compounds for the therapy of most patients with tuberculosis, it was relegated to use for patients with disease resistant to other antituberculosis drugs (1). Early reports contained no evidence for hematologic toxicity. More recently instances of sideroblastic anemia have been found during treatment with the antituberculosis drugs, cycloserine and pyrazinoic acid amide (2). This paper reports
MCCURDY PR, DONOHOE RF, MAGOVERN M. Reversible Sideroblastic Anemia Caused by Pyrazinoic Acid (Pyrazinamide®). Ann Intern Med. 1966;64:1280–1284. doi: 10.7326/0003-4819-64-6-1280
Download citation file:
© 2019
Published: Ann Intern Med. 1966;64(6):1280-1284.
DOI: 10.7326/0003-4819-64-6-1280
Hematology/Oncology, Red Cell Disorders.